<?xml version="1.0" encoding="UTF-8"?>
<p>Strategies for passive and active immunization to combat and prevent SARS-CoV-2 infection should take into account the pathogenesis of COVID-19, which can lead to death. The inflammatory response to SARS-CoV-2 is thought to drive or at least exacerbate the disease process, particularly during the second week after infection becomes symptomatic. How may these immune responses that modulate pathogenesis be affected by NAbs?</p>
